Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis

Journal of Clinical Immunology

Volumn 24, Issue 4, 2004, Pages 370-378

  Saidenberg Kermanac'h, Nathalie ^a   Bessis, Natacha ^a   Lemeiter, Delphine ^a   De Vernejoul, Marie Christine ^b   Boissier, Marie Christophe ^a   Cohen Solal, Martine ^b  

^a UNIVERSITÉ PARIS 13   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Bone loss; Collagen induced arthritis; IL 4; Osteoprotegerin; Rheumatoid arthritis

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; COLLAGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; OSTEOPROTEGERIN; PYRIDINOLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE DENSITY; BONE MINERAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; EVALUATION; FIBROBLAST; GENE THERAPY; GENETIC TRANSFECTION; HISTOPATHOLOGY; INFLAMMATION; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; SCORING SYSTEM; SPLEEN CELL; STATISTICAL SIGNIFICANCE; SUPERNATANT; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS; BONE RESORPTION; CELL LINE; COLLAGEN; DRUG THERAPY, COMBINATION; FIBROBLASTS; GENE THERAPY; GLYCOPROTEINS; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-4; MALE; MICE; MICE, INBRED DBA; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSFECTION;

EID: 3442877945     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOCI.0000029116.12371.bf     Document Type: Article

References (52)

1. Kelly C, Bartholomew P, Lapworth A, Basu A, Hamilton J, Heycock C: Peripheral bone density in patients with rheumatoid arthritis and factors which influence it. Eur J Intern Med 13:423, 2002
2. Harrison BJ, Hutchinson CE, Adams J, Bruce IN, Herrick AL: Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann Rheum Dis 61:1007-1011, 2002
3. Laan RF, van Riel PL, van de Putte LB: Bone mass in patients with rheumatoid arthritis. Ann Rheum Dis 51:826-832, 1992
4. Pisetsky DS: Tumor necrosis factor blockers in rheumatoid arthritis. N Engl J Med 342:810-811, 2000
5. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Modesale B: Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283:666-668, 1980
6. Cathcart ES, Hayes KC, Gonnerman WA, Lazzari AA, Franzblau C: Experimental arthritis in non human primates. Induction by bovine type II collagen. Lab Invest 54:26-31, 1986
7. Boissier MC, Feng XZ, Carlioz A, Roudier R, Fournier C: Experimental autoimmune arthritis in mice. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis. Ann Rheum Dis 46:691-700, 1987
8. Yasuda H, Shima N, Nakagawa N, Mochizuki S, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337, 1998
9. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cells 93:165-176, 1998
10. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki SI, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602, 1998
11. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luethy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997
12. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, Nagata N: Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the action of stromal cells with the osteoclast. Biochem Biophys Res Commun 250:229-234, 1998
13. Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan CR: A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrp, and 1,25 (oh)2D3. J Bone Miner Res 14:1478-1485, 1999
14. Horwood NJ, Kartsogiannis V, Quinn JMW, Romas E, Martin TJ, Gillepsie MT: Activated T cells support osteoclast formation in vitro. Biochem Biophys Res Commun 265:144-150, 1999
15. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309, 1999
16. Kotake S, Udagawa N, Hadoka M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A, Tomatsu T, Suda T, Kamatani N: Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44:1003-1012, 2001
17. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S: Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255-259, 1996
18. Saidenberg-Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC: Osteoprotegerin and inflammation. Eur Cytokine Netw 13:144-153, 2002
19. Saidenberg-Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC: Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 71:9-13, 2004
20. Wei S, Wang MW, Teitelbaum SL, Ross FP: Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J Biol Chem 277:6622-6630, 2002
21. Bendixen AC, Shevde NK, Dienger KM, Willson TM, Funk CD, Pike JW: IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA 98:2443-2448, 2001
22. Abu-Amer Y: IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest 107:1375-1385, 2001
23. Nakano Y, Watanabe K, Morimoto I, Okada Y, Ura K, Sato K, Kasono K, Nakamura T, Eto S: Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice. J Bone Miner Res 9:1533-1539, 1994
24. Woods JM, Katschke KJ, Volin MV, Ruth JH, Woodruff DC, Amin MA, Connors MA, Kurata H, Arai K, Haines GK, Kumar P, Koch AE: IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol 166:1214-1222, 2001
25. Bessis N, Cottard V, Saidenberg-Kermanach'h N, Lemeifer D, Fournier C, Boissier MC: Syngeneic fibroblasts transfected with a plasmid encoding interleukin-4 as non-viral vectors for anti-inflammatory gene therapy in collagen-induced arthritis. J Gene Med 4:300-307, 2002
26. Cottard V, Mulleman D, Bouille P, Mezzina M, Boissier MC, Bessis N: Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther 7:1930-1939, 2000
27. Bessis N, Honiger J, Damotte D, Minty A, Fournier C, Fradelizi D, Boissier MC: Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA). Clin Exp Immunol 117:376-382, 1999
28. Bessis N, Chiocchia G, Kollias G, Minty A, Fournier C, Fradelizi D, Boissier MC: Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. Clin Exp Immunol 111:391-396, 1998
29. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159:1689-1699, 2001
30. Triantaphyllopoullos KA, Williams RO, Tailor H, Chernajovsky Y: Amelioration of collagen-induced arthritis and suppression of interferon-γ, interleukin-12 and tumor necrosis factor α production by interferon-β gene therapy. Arthritis Rheum 42:90-99, 1999
31. Platzer C, Richter G, Uberla K, Hock H, Diamenstein T, Blankenstein T: Interleukin-4 mediated tumor suppression in nude mice involves interferon-gamma. Eur J Immunol 22:1729-1733, 1992
32. Bessis N, Doucet C, Cottard V, Douar AM, Firat H, Jorgensen C, Mezzina M, Boissier MC: Gene therapy for rheumatoid arthritis. J Gene Med 4:581-591, 2002
33. Boissier MC, Chiocchia G, Ronziere MC, Herbage D, Fournier C: Arthritogenicity of minor cartilage collagens (type IX and type XI) in mice. Arthritis Rheum 33:1-8, 1990
34. Bessis N, Boissier MC, Ferrara P, Blankenstein T, Fradelizi D, Fournier C: Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 26:2399-2403, 1996
35. Haugeberg G, Orstavik RE, Uhlig T, Falch JA, Halse JI, Kvien TK: Bone loss in patients with rheumatoid arthritis: Results from a population-based cohort of 366 patients followed up for two years. Arthritis Rheum 46:1720-1728, 2002
36. Goldring SR, Gravallese EM: Mechanisms of bone loss in inflammatory arthritis: Diagnosis and therapeutic implications. Arthritis Res 2:33-37, 2000
37. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, Martin TJ, Gillespie MT: Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 43:821-826, 2000
38. Itonaga I, Fujikawa Y, Sabokbar A, Murray DW, Athanasou NA: Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 192:97-104, 2000
39. Toritsuka Y, Nakamura N, Lee SB, Hashimoto J, Yasui N, Shino K, Ochi T: Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis. J Rheumatol 24:1690-1696, 1997
40. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S: Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259-269, 2000
41. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, Dunstan CR, Martin TJ, Gillespie MT: Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161:1419-1427, 2002
42. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Gortz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS: Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48:2042-2051, 2003
43. Campagnuolo G, Bolon B, Feige U: Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 46:1926-1936, 2002
44. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G: Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110:1419-1427, 2002
45. Riancho JA, Zarrabeitia MT, Mundy GR, Yoneda T, Gonzalez-Macias J: Effects of interleukin-4 on the formation of macrophages and osteoclast-like cells. J Bone Miner Res 8:1337-1344, 1993
46. Bendixen AC, Shevde NK, Dienger KM, Willson TM, Funk CD, Pike JW: IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA 98:2443-2448, 2001
47. Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, Richards CD, Miossec P, van Den Berg WB: IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 105:1697-1710, 2000
48. Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegard D, van den Berg WB: Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1:81-91, 1999
49. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD: Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 166:3499-3505, 2001
50. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600-605, 2000
51. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells. J Biol Chem 272:25190-25195, 1997
52. Hofbauer LC, Heuefelder AE: The role of osteoprotegerin and receptor activator of nuclear κB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 44:253-258, 2001